IV Administration of 14C-LY2606368
Research type
Research Study
Full title
Disposition of [14C]LY2606368 following Intravenous Administration in Patients with Advanced and/or Metastatic Solid Tumours
IRAS ID
184759
Contact name
Daniel Palmer
Contact email
Sponsor organisation
Eli Lilly and Company
Eudract number
2015-003126-13
Clinicaltrials.gov Identifier
15/NWW/0854, REC Reference
Duration of Study in the UK
1 years, 6 months, 16 days
Research summary
LY2606368 works by inhibiting a protein which is known to have a role in tumour cell growth. Current cancer treatments often damage DNA as part of their action and can therefore result in severe side effects. It is hoped that LY2606368 can be effective as a cancer treatment as an alternative to the DNA damaging agents.
This Study will involve a single dose of 170 mg 14C radiolabelled LY2606368 (Study Drug). This means that a radioactive substance, Carbon 14, (a naturally occurring radioactive version of carbon), will be incorporated into the Study Drug which will help us to investigate the Study Drug and its breakdown products to find out how much of these pass from the blood into urine, faeces and expired air. All subjects will receive the same dose of the Study Drug.REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
15/NW/0854
Date of REC Opinion
25 Jan 2016
REC opinion
Further Information Favourable Opinion